ALTERITY THERAPEUTICS LTD
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
ATHE | NDAQ
Overview
Corporate Details
- ISIN(s):
- US7397272045 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- LEVEL 3, 460 BOURKE STREET, 0 MELBOURNE
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Alterity Therapeutics is a clinical-stage biotechnology company dedicated to developing first-in-class, disease-modifying treatments for neurodegenerative disorders. The company's primary focus is on therapies that inhibit the aggregation of pathological proteins implicated in conditions such as Parkinsonian disorders and Multiple System Atrophy (MSA). Its lead drug candidate, ATH434, is an oral agent that has demonstrated efficacy in multiple animal models and is being evaluated in Phase 2 clinical trials. Alterity aims to create novel therapeutic options to disrupt the progression of these debilitating diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ALTERITY THERAPEUTICS LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALTERITY THERAPEUTICS LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALTERITY THERAPEUTICS LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
